INBX
What one share of Inhibrx Biosciences holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary modular protein engineering platforms. We leverage our innovative protein engineering technologies and deep understanding of target biology to create therapeutic candidates with attributes and mechanisms we believe to be superior to current approaches and applicable to a range of challenging, validated targets with high potential.
Inhibrx Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$8.88 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$8.47 |
| Cash and investments | $9.07 |
| Debt | $11.98 |
| Book value | −$3.60 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.15 | −$20.48 | $0.39 | −$16.80 | — | — |
| 2024 | $0.01 | $112.62 | $0.17 | −$13.15 | — | $9.23 |
| 2025 | $0.08 | −$9.04 | $0.00 | −$8.38 | — | $0.55 |